Stem Cell Clinic

Voices Against Brain Cancer Comments on New Study Claiming Fat Tissue Stem Cells can Fight Brain Cancer

Medical Daily reports on a new study where stem cells from fat tissue were used to help track difficult regions in the brain prone to remission. Voices Against Brain Cancer releases a statement encouraging more stem cell research.

New York, NY (PRWEB) April 18, 2013

According to the Medical Daily article by Ansa Varughese, the study showed that stem cells from fat tissue can be used to track difficult regions in the brain prone to remission. Scientists cannot yet determine why or how these stem cells target the prone areas, but the cells seem naturally drawn to the damaged areas. Researchers are using the stem cells as transporters to help deliver drugs for treatment in the cancer spreading regions of the brain.

Alfredo Quinones-Hinojosa, the lead researcher and professor of neurosurgery, oncology, and neuroscience at Johns Hopkins, was quoted in the article as saying, The biggest challenge in brain cancer is the migration of cancer cells. Even when we remove the tumor, some of the cells have already slipped away and are causing damage somewhere else. Building off our findings, we may be able to find a way to arm a patient's own healthy cells with the treatment needed to chase down those cancer cells and destroy them. It's truly personalized medicine.

The Medical Daily article goes on to mention that harvesting the mesenchymal stem cells from the fat tissue is safer than getting the cells from bone marrow. While it will still take years before a clinical trial happens in the U.S., the new stem cell treatment could play a major part in battling brain cancer.

Michael Klipper, Chairman of VABC, offers his comments on the new study. This is a great step toward battling brain cancer. While its still a new study, it seems to be having positive results, and can hopefully become something used in brain cancer treatment in the future. Dealing with brain tumors and the treatment after can be a major, painful ordeal. Hopefully this new study will lead to a new way patients can be treated after theyve had a tumor removed.

VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organizations research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.

#####

Alicia McAllister 5W Public Relations 646-430-5155 Email Information

Here is the original post:
Voices Against Brain Cancer Comments on New Study Claiming Fat Tissue Stem Cells can Fight Brain Cancer

Stem cell donor ditches Stanford University professor

MUMBAI: Healthy stem cells from a person of the same genetic make can mean life for Stanford University professor Nalini Ambady, or death if she doesn't find a donor in a month's time. A matching donor, recently found in Mumbai after an almost six-month-long search across India, backed out after initially consenting to stem-cell donation.

When her eight-year-old leukemia made a comeback last year, doctors in the US suggested she look for an Indian donor for a greater match probability, given ethnic similarities. After failing to find a match in the US' National Marrow Donor Program (NMDP) that boasts of a database of 10 million registered donors, Ambady's family finally directed their search towards India last November. Yet, two prominent stem cell donor registries in India with a combined pool of 50,000 donors could not find a match until recently.

Beating the odds of one in over 20,000, the unexpected happened last week when city-based Marrow Donor Registry of India (MDRI) found the Human Leukocyte Antigens (HLAs) match in a software engineer. HLA match refers to immunological compatibility, and doctors look for a match in at least 10 counts of crucial antigens to go ahead with a transplant. Coincidentally, not only did the donor hail from Ambady's hometown in Kerala, six out of 10 HLA parameters also matched. But Ambady's hopes crashed when after initially giving consent and registering as a donor, the engineer refused to go ahead with the donation citing health and later family problems.

Several rounds of counselling by members of MDRI, including founder head Sunil Parekh, did not cut much ice. Parekh said this was the sixth instance where the registry failed to convert a match into a transplant. Ambady's family and students have started a massive campaign across social media websites to hunt for a donor in time.

"Since we started the registry in 2010, there have been 55 requests for a match and we have managed to find six matches so far. But barring one instance, the donors backed out in all cases," he said, adding donor attrition has emerged as the biggest problem in the way of unrelated stem-cell transplants in the country.

While over 500 related stem cell transplants are carried out to cure leukemia, lymphoma and several other life-threatening cancers in the country annually, the numbers drop to almost one-tenth when it comes to transplants through unrelated donors. Also, in most of the unrelated stem cell transplants, the cells have to be imported from the US. "Just because the cells are imported, the cost of transplant could go up to around Rs 50 lakh and therefore remains out of bounds for the majority," said Dr Navin Khattry of Tata Memorial Hospital's Advanced Centre for Treatment, Research and Education in Cancer, which is the only one to carry out unrelated transplants in Mumbai. "The solution to this is obviously having a larger database of Indian donors," he said.

In global registries too, ethnic groups, particularly Asians, are not too well represented, which majorly reduces their chances of finding a match. According to Parekh, the problem of donor attrition only aggravates it and adds to the higher mortality rate. Donor attrition is usually due to apprehensions about the process and its long-term outcome. However, Parekh said stem cell donation, like blood donation, has no long-term effects on the donor and cells are replenished in six to eight weeks.

However, Raghu Rajagopal, the co-founder and CEO of Datri, which has the biggest database of 36,000 registered stem cell donors, said even global registries face an attrition of about 50%. "But in their case, if one donor backs out, there would be three more willing to come forward," he said.

Datri has also been holding camps for Ambady in Kochi. Ambady's family and friends, however, have appealed that only those who are serious about donating should come forward.

Read the original post:
Stem cell donor ditches Stanford University professor

Stem Cell Treatment in India for Diabetes : Testimonial – Video

Stem Cell Treatment in India for Diabetes : Testimonial
Stem cell treatment of diabetes is indicated at all stages of the disease. It is, however, the most effective in the cases of: New-onset insulin-dependent di...

By: StemRx BioScience

View original post here:
Stem Cell Treatment in India for Diabetes : Testimonial - Video

Japanese Firm Luring Investors With Nobel-Winning Technology

Retina Institute Japan K.K., which is employing Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month ahead of a possible initial public offering in five years.

The company, based in Fukuoka City, Japan, will raise 1 billion yen ($10.2 million) from the sale to fund development of a treatment for age-related macular degeneration -- a leading cause of blindness in the elderly -- using technology developed by Riken, Japans state-controlled research institute, Chief Executive Officer Hardy Kagimoto said in an interview.

After raising about 32 billion yen so far from investors, Retina is developing technology from a discovery that won Shinya Yamanaka, a professor at Kyoto University, the Nobel Prize for medicine in October. Yamanaka discovered a way to turn ordinary skin cells into what are called induced pluripotent stem, or iPS, cells.

The development of retina treatment with iPS cells can lead to development of the cell-utilized therapies for a wide range of diseases, said Akitsu Hotta, an assistant professor at Kyoto University who studies stem cells. Retinas commercialization of the technology will be a big milestone.

Retina last month estimated the potential market for its treatments at $21 billion.

The sale of a 3 percent stake values Retina at 33 billion yen. Dainippon Sumitomo Pharma Co. (4506), which paid 1.5 billion yen for 5 percent of Retina, jumped as much as 8 percent in Tokyo trading the day after that deal was announced in March.

Shin Nippon Biomedical Laboratories Ltd. (2395), which said April 9 that it plans invest 300 million yen in Retina, jumped as much as 12 percent today. Tella Inc. (2191), which is buying 100 million yen of shares in the company, was up 7.4 percent. Both stocks have more than quadrupled over the past six months.

Investors are rushing to buy shares of companies that are involved in stem-cell therapy and treatment technologies, said Tsutomu Yamada, a Tokyo-based analyst at Kabu.com Securities Co.

Kagimoto, 36, declined to name the companies participating in the current round of fundraising and said he has no plans to sell shares to local or foreign private equity firms.

Retina is targeting an IPO in five years in Japan and the U.S. to finance commercialization of the treatment, said Kagimoto, whos also a medical doctor. The company will conduct a clinical trial in Japan for treatment for age-related macular degeneration, and similar testing in the U.S., he said.

See the rest here:
Japanese Firm Luring Investors With Nobel-Winning Technology

Sen. Carrell to receive stem cell transplant soon

OLYMPIA, Wash.

Republican state Sen. Mike Carrell, who has a blood condition and has been hospitalized since last month, will receive a stem cell transplant from his brother next week.

In an email sent to constituents this week, Carrell says he started initial treatment on Wednesday at the Seattle Cancer Care Alliance. He said that the 100-day process begins with low doses of chemotherapy to lower his body's defenses and help increase his chances that next Tuesday's procedure will be successful.

Earlier this year, Carrell was diagnosed with myelodysplastic syndrome, also known as pre-leukemia. The chronic disease affects blood-forming stem cells.

Carrell was hospitalized last month after contracting a complicating illness while serving in Olympia, and he has not been back to the Capitol since. Republican leaders have said he would only be called back to the Legislature if his presence is needed for a crucial vote. Lawmakers are nearing the end of the 105-day session, which is set to end on April 28.

Carrell said he'll first undergo a low dose of full-body radiation, and then within a few hours will be injected with his brother's stem cells.

"Doctors are hopeful that my brother's healthy stem cells will march in and take over for the weakened marrow cells in my body," he wrote.

Visit link:
Sen. Carrell to receive stem cell transplant soon

Stem cell senescence drives aging, study suggests

Apr. 18, 2013 Declining levels of the protein BubR1 occur when both people and animals age, and contribute to cell senescence or deterioration, weight loss, muscle wasting and cataracts. Mayo Clinic researchers have shown that adult progenitor or stem cells -- important for repair and regeneration of skeletal muscle and maintenance of healthy fat tissue -- are subject to cellular senescence, and that clearance of these cells limits age-related deterioration of these tissues.

The findings appear today online in the journal Cell Reports.

BubR1 is an essential part of the mitotic checkpoint, the mechanism controlling proper cell division or mitosis. Without sufficient levels of BubR1, chromosomal imbalance will occur, leading to premature aging and cancer. Using mutant mice that expressed low levels of BubR1, the researchers found development of dysfunctional tissue with impaired cell regeneration. In analyzing the progenitor populations in skeletal muscle and fat, they found that a subset of progenitors was senescent and that the tumor suppressor p53 was acting to prevent this from happening through activation of p21.

"Earlier we discovered that senescent cells accumulate in tissues with aging and that removal of these cells delays age-related functional decline in these tissues," says Jan van Deursen, Ph.D., a Mayo Clinic molecular biologist and senior author of the study. "The key advance of the current study is that the progenitor cell populations are most sensitive for senescence, thereby interfering with the innate capacity of the tissue to counteract degeneration."

Not only do the findings contribute to knowledge on cell senescence as it relates to aging and related diseases, but understanding the mechanisms may lead to future therapies, say the researchers.

Co-authors include Darren Baker, Ph.D., and Robbyn Weaver both of Mayo Clinic.

The research was supported by the Ellison Medical Foundation, the Noaber Foundation, the National Institutes of Health (CA96985 and AG41122), and the Mayo Clinic Robert and Arlene Kogod Center on Aging.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Follow this link:
Stem cell senescence drives aging, study suggests

Read in

VATICAN: A girl whose bones used to break every two months was awarded for her courage in successfully battling her disease during a stem cell research conference at the Vatican.

It feels amazing to win an award like this, said Elizabeth Lobato, who was given the Pontifical Hero Award April 11 at the Second International Adult Stem Cell Conference in Vatican City.

I heard I was the first to get this award from Rome and thats awesome, said the 14-year-old in an interview with CNA.

Elizabeth was diagnosed with osteogenesis imperfecta, commonly known as brittle bone disease, when she was just 10 months old. People affected by illness - which is caused by a genetic defect - often suffer from muscle weakness, hearing loss, loose joints, curved bones, scoliosis, brittle teeth and short stature.

But the teenager has grown over 13 inches since she began the adult stem cell treatment that involves her receiving bone marrow-derived stem cells from her father.

The teenager, still small for her age and currently in a wheelchair, is in Rome with her parents attending a conference promoting adult stem cell research.

The conference began April 11 at the Vaticans New Synod Hall under the co-sponsorship of the Pontifical Council for Culture and the New York City-based Stem for Life Foundation.

The first gathering was held back in Nov. 2011, but as the group of physicians, philanthropists and patients assembled in the Vatican hall today, the sense of excitement was palpable.

Since then it seems the entire world has awakened to a simple reality that adult stem cell therapies have the potential to usher in a new era of health and healing, said Doctor Robin Smith, chairman and president of the Stem for Life Foundation.

Adult stem cell therapies hold the promise to vanish countless diseases and dangerous medical conditions, to turn the tide of human suffering, to transform modern-day health care from one that focuses on managing symptoms to one that develops cures, she said.

Original post:
Read in